3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 3
2
Phase 2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
1
Head & Neck
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
8
Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Leukemia, Myeloid, Acute
4
Hematologic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Pulmonary Disease, Chronic Obstructive
2
Neoplasm Metastasis
2
Lymphoma, Follicular
2
Leukemia
2
Colonic Neoplasms
2
COVID-19
2
Xerostomia
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Stroke
1
Stomatitis
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
Standard of Care
×
Clear all
NCT03575351
2025-08-03
TRANSFORM
Celgene
Phase 3
Completed
184 enrolled
30 charts
1 FDA
NCT02369874
2021-02-10
EAGLE
AstraZeneca
Phase 3
Completed
736 enrolled
26 charts